Catalys Pacific is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for patients in Asia and around the world. The company leverages its expertise in clinical development and regulatory know-how to bring therapies to market, with an emphasis on addressing unmet medical needs.

Catalys Pacific

Leveraging its networks in academia, biotech, venture capital and the pharmaceutical industry, Catalys Pacific has assembled a group of Strategic and Preferred Partners with whom to create asset-centric global bioventure companies.
Catalys Pacific begins operations as one of Japanʼs largest life sciences-focused investment firms. The firmʼs mission is to provide solutions to unmet medical needs for patients worldwide by creating and investing in companies that drive innovation in life sciences. Catalys Pacific maintains a strictly independent governance structure that ensures autonomous assessment and decision-making of its investments.

HilleVax

Mineralys Therapeutics

Phathom Pharmaceuticals

Phathom Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced VOQUEZNA® (#vonoprazan) tablets for Erosive GERD and associated heartburn added to Express Scripts' national formularies.

#Phathom #GERD 

Read the release to learn more: 
https://lnkd.in/gq8QaDgw

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, announced final results from a Phase 2 study of TPN-101 for the treatment of Progressive Supranuclear Palsy and interim results from a Phase 2 study of TPN-101 for the treatment of C9orf72-related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia.

#Transposon #PSP #ALS #FTD 

Read the release to learn more: 
https://lnkd.in/gtFgTrTw

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, announced $120 Million Private Placement Financing.

#Mineralys #PIPE 

Read the release to learn more: 
https://lnkd.in/g9DDsZiF

Today Renalys Pharma, Inc. was launched for developing medicines and treatments for Asian patients with renal disease.

Renalys Pharma’s efforts are centered on bringing #sparsentan, an investigational dual-acting treatment developed by #Travere Therapeutics, to IgA nephropathy patients in Japan and selected Asian countries. 

#IgAN

Read the release to learn more: 
https://lnkd.in/gPXz-e7V


We are pleased to announce that Mr. Ryutaro Shimazaki, a former Executive Officer at Kyowa Kirin Co., Ltd., has joined the team as a Partner.

He will contribute to our #inbound strategy to create new #biotech companies in Japan and to eliminate the drug lag between Japan and other countries through new #drug development.

See our release for more information:
https://lnkd.in/gifZ66Kf

COM:CATALYSPACIFIC

Catalys Pacific

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

Description

invested in

Metrics